Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2014. The report details a specific share repurchase transaction executed on February 6, 2014, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 537,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,594.50 pence per share; lowest price paid was 1,561.50 pence per share.
- Treasury Holdings (Settled): 487,433,663 shares, representing 9.12% of total issued share capital.
- Treasury Holdings (Including Unsettled): 487,970,663 shares, representing 10.05% of total voting rights.
- Shares in Issue (Excluding Treasury): 4,857,235,434 shares.
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 537,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.05% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (487,970,663 including unsettled) against the company's latest capitalization table.
- Confirm the calculation of the 10.05% voting rights held in Treasury based on the 4,857,235,434 shares in issue.
- Review the Financial Conduct Authority's Disclosure and Transparency Rules to understand notification thresholds for shareholders based on the reported share count.